53732-26-6

Usage

Uses

Used in Pharmaceutical Industry:
1-(2-Chloro-5-Methylphenoxy)-2,3-epoxypropane is used as a key intermediate in the synthesis of Bupranolol (B689650), a medication designed to treat hypertension and tachycardia. As an antagonist at the cardiostimulatory low-affinity state of b(1)-adrenoceptors, Bupranolol helps regulate heart rate and blood pressure, making it a valuable compound in the management of cardiovascular conditions.
In the synthesis of Bupranolol, 1-(2-Chloro-5-Methylphenoxy)-2,3-epoxypropane plays a critical role in the formation of the final product, which is effective in treating patients with high blood pressure and rapid heart rate. 1-(2-Chloro-5-Methylphenoxy)-2,3-epoxypropane's unique structure allows for further chemical modifications and reactions, enabling the development of new therapeutic agents with potential applications in various medical fields.

Upstream product

• 615-74-7 2-chloro-5-methylphenol 
• 106-89-8 epichlorohydrin 
• 556-52-5 oxiranyl-methanol 

Downstream Products

• 14556-46-8 bupranolol 
• 15148-80-8 (R)-bupranolol hydrochloride 
• 61877-83-6 (+)-Bupranolol 
• 15148-80-8 (S)-bupranolol hydrochloride 
• 61877-83-6 (-)-Bupranolol 
• 133154-69-5 6-[3-[2-[3-(2-Chloro-5-methyl-phenoxy)-2-hydroxypropylamino]ethoxy]phenyl]-4,5-dihydro-5-methyl-3(2H)-pyridazinone 
• 133154-59-3 6-[4-[2-[3-(2-Chloro-5-methyl-phenoxy)-2-hydroxypropylamino]ethoxy]phenyl]-4,5-dihydro-5-methyl-3(2H)-pyridazinone 
• 133177-62-5 6-[2-[2-[3-(2-Chloro-5-methyl-phenoxy)-2-hydroxypropylamino]ethyl]benzimidazol-5-yl]-4,5-dihydro-3(2H)-pyridazinone 
• 89514-86-3 1-(2-Chloro-5-methylphenoxy)-3-[1,1-dimethyl-3-(3-chloro-6-pyridazinyloxy)propylamino]-2-propanol 
• 89514-71-6 1-(2-Chloro-5-methylphenoxy)-3-[1,1-dimethyl-2-(3-chloro-6-pyridazinylthio)ethylamino]-2-propanol 

Relevant academic research and scientific papers

Synthesis, phase behavior and absolute configuration of β-adrenoblocker bupranolol and related compounds

β-Blocker bupranolol 1, it's hydrochloride and their precursors 1-(2-chloro-5-methylphenoxy)-2,3-epoxypropane 2 and 3-(2-chloro-5-methylphenoxy)propane-1,2-diol 3 were prepared in racemic and single-enantiomer forms. For all the studied compounds phase behavior during crystallization was established on the basis of IR, DSC and X-ray investigations. Absolute configurations were established for compounds 1 and 2. Being conglomerate, racemic oxirane 2 was resolved by direct entrainment procedure. Being anticonglomerate, in the process of recrystallization, almost enantiopure 1·HCl accumulates in the mother liquor, not in the crystalline precipitate.

Continuous and convergent access to vicinyl amino alcohols

Five active pharmaceutical ingredients (APIs) containing the vicinyl amino alcohol moiety were synthesized using a convergent chemical assembly system. The continuous system is composed of four flow reaction modules: biphasic oxidation, Corey-Chaykovsky epoxidation, phenol alkylation, and epoxide aminolysis. Judicious choice of reagents and module order allowed for two classes of β-amino alcohols, aryl and aryloxy, to be synthesized in good (27-69%) overall yields.

LIGANDS FOR CARDIAC BETA1 ADRENOCEPTOR FOR IMAGING CONGESTIVE HEART FAILURE

Novel β1 adrenoreceptor ligands that find use as imaging agents within nuclear medicine applications (e.g., PET imaging and SPECT imaging) are provided. Methods of imaging, including methods of imaging congestive heart failure, are also provide